NCT03929887 (KORNERSTONE) is a clinical trial of Kidney Biopsy in Glomerular Disease, sponsored by Seoul National University Hospital.

Who is sponsoring NCT03929887?

NCT03929887 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT03929887?

Interventions in NCT03929887: Kidney Biopsy.

What condition does NCT03929887 study?

NCT03929887 studies Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy, Focal Segmental Glomerulosclerosis, Lupus Nephritis, Crescentic Glomerulonephritis.

Is NCT03929887 still recruiting?

NCT03929887 is currently recruiting now. Last updated 12 February 2020.

Last reviewed 2020-02-12 · How we verify

NCT03929887: KORNERSTONE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

Recruiting now Last updated 12 February 2020

What this trial tests

trial testing Kidney Biopsy in Glomerular Disease in 3,000 participants. Currently enrolling.

Timeline

1 May 2019

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	Seoul National University Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	1 May 2019
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	6 locations across South Korea

Drugs / interventions tested

Kidney Biopsy

Conditions studied

Glomerular Disease — all drugs for Glomerular Disease →
Minimal Change Disease — all drugs for Minimal Change Disease →
IgA Nephropathy — all drugs for IgA Nephropathy →
Membranous Nephropathy — all drugs for Membranous Nephropathy →

Sponsor

Seoul National University Hospital

Who can join

Eligibility, any sex, with Glomerular Disease or Minimal Change Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Glomerulonephritis (GN) generates an enormous individual and social economic burden. However, the therapeutic options are largely based on clinical and pathological parameters and the individual response to therapy or prognosis is uncertain. Recently, along with advances in molecular analysis and computational bioinformatics, genomic data from human renal biopsies could provide a strong foundation for the future of precision medicine in nephrology. In response to a request for applications by the Ministry of Health and Welfare of Korea for the creation of Clinical Research Registry, multi-center N network has been established for prospective cohort with kidney biopsy samples (KORNERSTONE). Through this Network the investigators hope to understand the fundamental biology of glomerulonephritis and aim to bank long-term observational data and corresponding biological data including genomic data from kidney tissues, and kidney pathologic data which is digitalized This database is archived to a web-based platform to access easily and further enrich for researchers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Biobanking for glomerular diseases: a study design and protocol for KOrea Renal biobank NEtwoRk System TOward NExt-generation analysis (KORNERSTONE).
Kang E, Kim Y, Kim YC, Kim E, et al · · 2020 · cited 5× · PMID 32842999 · DOI 10.1186/s12882-020-02016-z

Verify or expand the search:

Other trials of Kidney Biopsy

Trials testing the same drug.

NCT05896839 — Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metasta · Phase 1, PHASE2 · recruiting
NCT04916132 — Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors · recruiting
NCT04334707 — Kidney Precision Medicine Project · recruiting

Other recruiting trials for Glomerular Disease

Currently open trials in the same condition.

NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
NCT05505500 — Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. · recruiting
NCT00977977 — Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy · Phase 2 · recruiting

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03929887 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 12 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03929887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing